LGND:NASDAQ
Ligand Pharmaceuticals Inc
US$302,96
arrow_upward
+0,07%(+0,22) 1 HR
US$302,96
0,00% (0,00)
bedtimeSetelah jam perdagangan normal
Tutup: 2 Okt, 16.00.01 GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk LGND...
Pembukaan
US$307,55
Tinggi
US$307,63
Rendah
US$301,32
Kapitalisasi pasar
6,04Â M
Volume rata-rata
236,03Â rb
Volume
179,23Â rb
Rasio P/E
32,22
Harga tinggi dalam 52 minggu terakhir
US$326,63
Harga rendah dalam 52 minggu terakhir
US$175,89
EPS
US$9,40
Beta
1,06
Saham beredar
19,94Â jt
Jumlah karyawan
47
Pembukaan
US$307,55
Tinggi
US$307,63
Rendah
US$301,32
Kapitalisasi pasar
6,04Â M
Volume rata-rata
236,03Â rb
Volume
179,23Â rb
Rasio P/E
32,22
Harga tinggi dalam 52 minggu terakhir
US$326,63
Harga rendah dalam 52 minggu terakhir
US$175,89
EPS
US$9,40
Beta
1,06
Saham beredar
19,94Â jt
Jumlah karyawan
47
Artikel berita
Dari sumber web dan partner berita
Pluang
·
14 jam yang lalu
S&P 500 mendekati rekor tertinggi tapi sinyal k...
Vietnam.vn
·
2 hari yang lalu
Ringkasan Singkat 1-10: Imbal hasil obligasi AS mencapai level tertinggi sejak 2002, mendorong Dow Jones ke titik terendah dalam hampir empat bulan.
Pluang
·
14 jam yang lalu
Nasdaq capai rekor tertinggi setelah data tenag...
Pluang
·
2 jam yang lalu
Saham teknologi kuasai pemenang S&P 500 Septemb...
Profil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Tentang Ligand Pharmaceuticals Inc